The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

As the latest and most anticipated method of tumor immunotherapy, CAR-NK therapy has
received increasing attention in recent years, and its safety and high efficiency have …

Natural killer (NK) cells, a unique component of the innate immune system, are inherent
killers of stressed and transformed cells. Based on their potent capacity to kill cancer cells …

Cancer immunotherapy harnesses the body's immune system to combat malignancies,
building upon an understanding of tumor immunosurveillance and immune evasion …

Simple Summary Chimeric antigen receptor (CAR) cell-based therapy is a promising
treatment approach for glioblastoma, a fatal brain cancer with limited treatment options …

Glioblastoma is a malignant tumor with the highest morbidity and mortality in the central
nervous system. Conventional surgical resection combined with radiotherapy or …

Melanoma is among the most lethal forms of cancer, accounting for 80% of deaths despite
comprising just 5% of skin cancer cases. Treatment options remain limited due to the genetic …

Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is
always resistant to existing treatments, including surgical resection, postoperative …

Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell
therapy for malignancies. However, some obstacles, including side effects such as graft …